ESMO 2018: Single-Agent Nazartinib in EGFR-Mutant Lung Cancer
Posted: Tuesday, November 20, 2018
Treatment with the third-generation EGFR tyrosine kinase inhibitor nazartinib showed high response and disease control rates among patients with EGFR-mutated non–small cell lung cancer (NSCLC) with no prior treatment, according to a report presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich (Abstract LBA61). Daniel Shao Weng S. Tan, MRCP, of the National Cancer Centre, Singapore, and colleagues reported durable responses, including among patients with baseline brain metastases.
Eligible treatment-naive patients with EGFR-mutated NSCLC received the recommended phase II dose of nazartinib once daily on a continuous schedule. Of the 45 patients enrolled, 17 had baseline brain metastases.
The study reported an overall response rate of 64% (n = 29), including 1 complete response. Of the responding patients, 27 showed ongoing responses after the data cutoff. The majority of patients (91%) had a 6-month duration of response, and the disease control rate was 93%. The 6-month progression-free survival and 6-month overall survival rates were 83% and 95%, respectively. Of those with baseline brain metastases, 9 patients (53%) showed resolution of metastases after treatment. A new brain metastasis was reported in just 1 of the 27 patients who began treatment without baseline brain metastases.
The most common adverse events included diarrhea, maculopapular rash, stomatitis, cough, decreased appetite, pruritus, and pyrexia. Maculopapular rash was the most common grade 3 to 4 adverse event and was reported by 9% of patients. A total of 12 patients discontinued therapy due to progressive disease (n = 9), severe adverse events (n = 1), patient choice (n = 1), or death (n = 1).
